Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)

Next Previous
Trial Profile

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Apalutamide (Primary) ; Bicalutamide (Primary) ; Degarelix (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Histrelin (Primary) ; Leuprorelin (Primary) ; Methylprednisolone (Primary) ; Nilutamide (Primary) ; Prednisone (Primary) ; Triptorelin (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms VA STARPORT

Most Recent Events

  • 30 Jul 2025 Planned End Date changed from 1 Dec 2025 to 30 Mar 2029.
  • 30 Jul 2025 Planned primary completion date changed from 1 Jul 2025 to 31 Mar 2026.
  • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top